Dr VK Paul delivers lecture at NITI Aayog’s First India Development Strategies Lecture Series
Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic
Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic
Funds raised will be used to develop technology and foster healthcare partnerships
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Transformation to pure-play Innovative Medicines company nears completion
The #Heart2HeartChallengeIndia campaign is very simple – you have to climb 60 steps in a minute, make a video of it, share it on your social media, tag 5 people, inviting them to take this challenge to check their heart health
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
Azelis’ customers now have access to products including the well-established Polyglykol portfolio, as well as a brand-new range of Motusflex and VitiPure excipients.
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
Subscribe To Our Newsletter & Stay Updated